Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Merck Plans Gardasil Campaign Targeting “Mid-adult” Women

This article was originally published in The Pink Sheet Daily

Executive Summary

FDA clears Pennsylvania manufacturing plant; vaccine sBLAs, including one for Gardasil in “older” women, can proceed.

You may also be interested in...



Gardasil Label Expansion To Women 27-45 Delayed Until 2010, At The Earliest

Merck receives a second “complete response” letter from FDA related to its sBLA to extend indications for the vaccine to older women.

Gardasil Label Expansion To Women 27-45 Delayed Until 2010, At The Earliest

Merck receives a second “complete response” letter from FDA related to its sBLA to extend indications for the vaccine to older women.

Merck Compensates Docs For Gardasil For Adult Women When Insurers Do Not

Merck is encouraging physicians to provide the Gardasil human papillomavirus vaccine to young adult women by cushioning the risk that health plans may deny reimbursement for such patients

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS068131

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel